• LAST PRICE
    1.6300
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    1.6000/ 13
  • Ask / Lots
    1.6600/ 4
  • Open / Previous Close
    1.6500 / 1.6300
  • Day Range
    Low 1.6100
    High 1.6500
  • 52 Week Range
    Low 1.5600
    High 2.2700
  • Volume
    4,578
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 1.63
TimeVolumeABIO
09:32 ET2761.65
10:51 ET3001.6219
12:48 ET4951.6102
12:51 ET2001.6103
01:27 ET20001.61
04:00 ET1001.63
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesABIO
ARCA Biopharma Inc
23.6M
-4.4x
---
United StatesALRN
Aileron Therapeutics Inc
23.5M
-1.6x
---
United StatesAPRE
Aprea Therapeutics Inc
23.8M
-1.8x
---
United StatesFBRX
Forte Biosciences Inc
24.0M
-0.6x
---
United StatesAPTO
Aptose Biosciences Inc
23.1M
-0.2x
---
United StatesLSTA
Lisata Therapeutics Inc
24.4M
-1.1x
---
As of 2024-02-24

Company Information

ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company engaged in developing genetically and other targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. The Company's lead product candidate is Gencaro (bucindolol hydrochloride) for the treatment of atrial fibrillation (AF) in patients with chronic heart failure (HF). Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. Gencaro is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties that is developing for the treatment of atrial fibrillation in patients with heart failure. Its Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), is a protein therapeutic in clinical development as a potential treatment for patients with COVID-19. It is also evaluating options for development of its assets, including partnering and other strategic options.

Contact Information

Headquarters
Suite 430, 8001 Arista PlaceBROOMFIELD, CO, United States 80021
Phone
720-940-2200
Fax
302-655-5049

Executives

Independent Chairman of the Board
Robert Conway
President, Chief Executive Officer, Director
Michael Bristow
Chief Financial Officer
C. Jeffrey Dekker
Chief Operating Officer
Thomas Keuer
Director
James Flynn

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$23.6M
Revenue (TTM)
$0.00
Shares Outstanding
14.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.14
EPS
$-0.37
Book Value
$2.55
P/E Ratio
-4.4x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.